Article published by Jim O’Donoghue, President, S3 Connected Health on PharmaTimes on 2 January 2019.
The future will see the pharma industry change two things: what and how it sells. As payers become more focused on Value-Based Contracts (VBCs), the days of pay-per-pill are disappearing. Drugs will remain core but they will be augmented by a portfolio of digital therapies, wrap-around services and data analytics, which providers will pay for according to overall patient outcomes. But what are Digital Therapeutics, and what do they mean for pharma firms?
READ MORE about Value-Based Care and how will this macro driver impact Pharma in 2019.